The global investigational new drug (IND) CDMO market is experiencing robust growth as pharmaceutical innovation accelerates worldwide. The market, valued at USD 5.29 billion in 2024, is projected to surge to USD 10.34 billion by 2034, growing at a CAGR of 6.97% from 2025 to 2034. This growth is fueled by increasing drug development activities, AI-driven service platforms, and rising private and public investments in the pharmaceutical sector.
Market Overview
Contract Development and Manufacturing Organizations (CDMOs) play a critical role in helping pharmaceutical companies bring investigational new drugs (INDs) to market. With advanced technologies and global footprints, CDMOs offer end-to-end services, including preclinical development, clinical trial material manufacturing, and regulatory support.
Key Market Highlights
-
Market Size (2024): USD 5.29 billion
-
Market Forecast (2034): USD 10.34 billion
-
CAGR (2025–2034): 6.97%
-
Leading Region: North America (44–48% market share in 2024)
-
Fastest Growing Region: Asia Pacific
-
Top Segment (2024): Small Molecules (45–50% share)
-
Emerging Segment: Advanced Therapies (highest forecast CAGR)
Top Investigational New Drug CDMO Companies
1. AGC Biologics
About: AGC Biologics is a global CDMO known for its biologics and cell therapy expertise.
Products: Biopharmaceuticals, plasmid DNA, viral vectors.
Market Cap: Approx. USD 1.2 billion.
2. Albany Molecular Research Inc. (Curia)
About: Curia offers integrated drug discovery, development, and manufacturing solutions.
Products: APIs, biologics, drug product manufacturing.
Market Cap: Private (acquired by Carlyle Group in 2017).
3. Asymchem
About: A leading CDMO with a strong presence in China and the US, specializing in small molecule drugs.
Products: Process R&D, API production, formulation.
Market Cap: Approx. USD 5.1 billion.
4. Cambrex
About: Cambrex is a key player in small molecule drug development and manufacturing services.
Products: APIs, drug substances, finished dosage forms.
Market Cap: Private (acquired by Permira in 2019).
5. Catalent
About: Catalent delivers advanced solutions in drug delivery technologies and development.
Products: Biologics, gene therapy, oral and inhalation delivery.
Market Cap: Approx. USD 8.5 billion.
6. CordenPharma
About: CordenPharma specializes in APIs, excipients, and lipid nanoparticles for innovative drugs.
Products: Lipid synthesis, mRNA encapsulation, peptide APIs.
Market Cap: Private.
7. Eurofins CDMO
About: A division of Eurofins Scientific, providing comprehensive drug development services.
Products: API development, finished product manufacturing.
Market Cap: Parent company Eurofins Scientific: USD 13 billion.
8. Evotec
About: Evotec offers integrated solutions from drug discovery to manufacturing.
Products: Biologics, small molecules, cell therapy services.
Market Cap: Approx. USD 5.3 billion.
9. Fujifilm Diosynth Biotechnologies
About: A global CDMO with strong capabilities in biologics and advanced therapies.
Products: Viral vectors, monoclonal antibodies, cell culture systems.
Market Cap: Parent company Fujifilm Holdings: USD 25 billion.
10. Lonza
About: Lonza is one of the largest CDMOs globally, serving the pharmaceutical and biotech industries.
Products: Biologics, cell & gene therapies, APIs.
Market Cap: Approx. USD 38 billion.
11. MedPharm
About: MedPharm specializes in topical and transdermal drug delivery solutions.
Products: Semi-solid and liquid formulations, dermatology drugs.
Market Cap: Private.
12. Patheon (Thermo Fisher Scientific)
About: Patheon, under Thermo Fisher, provides integrated pharmaceutical development and manufacturing.
Products: APIs, drug products, packaging solutions.
Market Cap: Parent company Thermo Fisher: USD 215 billion.
13. PCI Pharma Services
About: PCI offers end-to-end solutions for drug development, including packaging and distribution.
Products: Clinical trial services, commercial manufacturing.
Market Cap: Private.
14. Piramal Pharma Solutions
About: A part of Piramal Pharma, it offers end-to-end development and manufacturing services.
Products: APIs, drug products, injectable formulations.
Market Cap: Approx. USD 2 billion.
15. Quotient Sciences
About: Quotient Sciences provides an integrated approach to speed up drug development timelines.
Products: Formulation development, clinical trial manufacturing.
Market Cap: Private.
Industry Trends Driving Growth
-
AI Integration: Platforms enhanced with AI for efficient drug development workflows.
-
Collaborations: Increased partnerships between pharmaceutical companies and CDMOs.
-
Regional Expansion: Emerging markets like Asia Pacific driving demand.
-
Government Support: Rising investments in pharmaceutical infrastructure globally.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
FAQs about the Investigational New Drug CDMO Market
1. What is the expected growth rate of the IND CDMO market?
The market is projected to grow at a CAGR of 6.97% between 2025 and 2034.
2. Which region dominates the IND CDMO market?
North America leads with a 44–48% share as of 2024.
3. Who are the top players in the market?
Key companies include Lonza, Catalent, Thermo Fisher (Patheon), AGC Biologics, and Fujifilm Diosynth.
4. What factors are driving the market growth?
Increased drug development, AI-driven services, and government investments are major growth drivers.
5. Which segment is growing fastest by molecule type?
Advanced therapies are expected to register the highest CAGR during the forecast period.
Source : https://www.towardshealthcare.com/insights/investigational-new-drug-cdmo-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5866
About the Author
